A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis

Figures & data

Figure 1. Schematic representation of the model structure.

Figure 2. HAQ-DI score distribution at baseline (RA-BEAM, modified intention-to-treat population).

Figure 3. Convergence assessment, total QALYs and total costs.